



In situ forming implants (ISFIs) are an innovative method of drug delivery that serve to 
overcome many of the issues faced by oral daily pills in HIV Pre-Exposure Prophylaxis (HIV 
PrEP). Specifically, the difficulty patients have with daily pill compliance to a daily regimen.  ISFI 
systems are subcutaneous injections that release drug over an extended period of time, which can 
potentially mitigate the variability in adherence to a daily pill for HIV Pre-Exposure Prophylaxis. 
The implants are composed of Poly(DL-lactide-co-glycolide) (PLGA) polymer, N-methyl-2-
pyrrolidone (NMP), and an antiretroviral drug. Changing the composition of the ISFI formulation 
provides the ability to fine-tune drug release kinetics.  In this study we have investigated the effect 
of the following formulation parameters on drug release kinetics in vitro: 1) the ratio of glycolic 
acid (GA) to lactic acid (LA) of PLGA (85:15, 75:25, 65:35); 2) the molecular weight of PLGA 
(53 kDa, 27 kDa, 10 kDa); and 3) drug properties (Dolutegravir, Lamivudine, and Emtricitabine). 
Due to differences in the structure of glycolic acid and lactic acid, specifically an additional methyl 
side chain present in lactic acid that increases its hydrophobicity, the formulations with a higher 
proportion of glycolic acid will exhibit more hydrophilic qualities.  Thus, formulations with PLGA 
with a higher ratio of glycolic acid to lactic acid will undergo ester hydrolysis at a faster rate 
resulting in increased release kinetics. The formulation containing the highest PLGA MW 
exhibited markedly slower release kinetics of dolutegravir due to reduced degradation of the ester 
linkages over time. From the study investigating the effect of drug properties on its release from 
the ISFI, lamivudine and emtricitabine, hydrophilic drugs, released significantly faster than did 
dolutegravir, a hydrophobic drug. In addition to fine-tuning release kinetics through altering 
formulation parameters in the ISFI formulation, different co-solvents were tested with NMP in 
order to optimize dolutegravir’s solubility in the ISFI to meet the human dose requirement for HIV 
PrEP (i.e. [DTG] ≥ 300 mg/mL). Several co-solvents showed increased solubility compared to 





















Despite decades of research, globally ~37 million people are living with HIV and ~2.0 
million people are newly infected with the virus every year [1]. Any person has the potential to 
contract HIV; however, there are certain areas and groups of people that can be deemed “at high-
risk”. These areas are largely located in sub-Saharn Africa.  Africa has ~4.2% prevalence of HIV 
(i.e. ~1 in every 25 people) whereas the Americas, the continent with the next highest prevalence 
of HIV, only has a prevalence of 0.5% [1].  HIV Pre-Exposure Prophylaxis (PrEP) is preventative 
method for high-risk individuals to prevent HIV infection.  This treatment serves to inhibit the 
virus from establishing permanent infection [2].  Current methods of PrEP are dominated by daily 
oral pill treatments known as Truvada®. Although effective, adherence to a daily oral pill has been 
proven to be difficult.  
Currently there are two long-acting formulations (long acting implants – LAIs) in clinical 
trials for HIV prevention: GSK 744-LA and TMC 278-LA.  GSK 744-LA, cabotegravir (CAB 
LA), is an integrase inhibitor in Phase III development for HIV treatment and prevention. 
Similarly, TMC 278-LA, Rilpivirine LA, is in Phase III development as a non-nucleoside reverse 
transcriptase inhibitor. Both deliver sufficient doses to prevent potential HIV infection.  However, 
there are several concerns and complications associated with these formulations. Both use Elan 
Nanocystral Technology to develop the implants.  Not only does this include a complex milling 
process of the drug and a drug stabilizer to obtain nanoparticles, but it also results in variability in 
size.  The range of sizes leads to a lack of reproducibility and predictability of pharmacokinetic 
releases.  Further, nanoparticle formulated long-acting injectable drugs cannot be removed once 
injected.  This poses consequential effects in the event of an infection or another adverse drug 
event.  In order to account for the inability of removal, these injectables require a 4-week ‘lead-in’ 
oral regimen to meet current safety standards. An oral regimen of the drug is also required if the 
injectables are to be discontinued. Thus, the efficacy of these injectables are still contingent on the 
adherence to an oral regimen. 
Subcutaneous injections of an in-situ forming implant (ISFI) is a state-of-the-art, long 
acting alternative to oral HIV PrEP. An ISFI is loaded with antiretroviral drug, like dolutegravir 
(DTG, integrase inhibitor), which allows long-acting drug release over ≥30 days.  The components 
of the ISFI system are PLGA polymer, N-methyl-2-pyrrolidone (NMP) – an organic solvent, and 
drug.  NMP has been shown to be the superior organic solvent used in ISFI systems due to its 
solubilizing ability with drug and its favorable interaction with PLGA [6].  The PLGA is a polymer 
made up of glycolic acid (GA) and lactic acid (LA), varying the amount and proportions of each 
changes the molecular weight and ratio of GA to LA, respectively. The manufacturing of the ISFI 
system is far simpler compared to LAIs, as the ISFI system is only comprised of three components. 
The water-miscible solvent, NMP, diffuses into the surrounding space which leaves behind an 
insoluble implant, or depot, of drug and polymer. Due to the solid structure of the depot the ISFI 
can be removed from the body in the case of pregnancy or an adverse drug event. The simplicity 
and efficacy of the ISFI system make it superior to other treatments for the treatment in HIV PrEP.  
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In order to identify the formulation parameters that provide the ability to fine-tune the 
release kinetics of the drugs from the ISFI system, we investigated the effect of GA:LA ratio in 
PLGA and the effect of PLGA MW on the release kinetics of dolutegravir in vitro. Three different 
PLGAs were used in the molecular weight study: 10 kDa, 27.2 kDa, and 53.4 kDa. The different 
release of DTG was recorded over many weeks to establish a pattern among the different PLGAs 
in formulation.  Similarly, three PLGAs of the same molecular weight and different GA:LA ratios 
were used in a release study to determine the effect of the ratio of glycolic acid to lactic acid on 
the release rate of dolutegravir. 
The type of drug used in ISFI formulations also impacts the release kinetics depending on 
physical and chemical characteristics.  Dolutegravir (DTG), lamivudine (3TC), and emtricitabine 
(FTC) were formulated at 10 wt% in an ISFI consisting of PLGA (50:50 GA/LA, MW 27 kDa) 
and NMP (1:2 w/w PLGA/NMP) to investigate the effect of drug physical/chemical properties on 
its release kinetics from the ISFI in vitro.  The drugs can interact favorably with the PLGA or the 
water-miscible solvent depending on their relative hydrophilic or hydrophobic natures determined 
by their chemical structure.  Hydrophilic drugs (i.e. FTC and 3TC) will favorably interact with the 
solvent which should result in faster release kinetics; dissimilarly, hydrophobic drugs (i.e. DTG) 
will more favorably interact with the PLGA thus releasing at a slower rate.  
Our goal for optimal translation to human dose for HIV PrEP is to achieve [DTG] ≥300 
mg/mL. In order to maximize solubility and limit use of an organic solvent (i.e. NMP), co-solvents 
were tested in varying ratios with NMP to determine if the solubilizing ability of the organic 
solvent can be enhanced for DTG. Co-solvent solutions were super saturated with DTG and 
analyzed via HPLC to obtain a quantitative, maximum concentration of DTG in the co-solvent 
systems.  NMP is the favorable organic solvent in ISFI systems [6], however it is a class 2 
biocompatible solvent [7] which the FDA dictates limited use in the body due to inherent toxicity 
at a certain level.  Thus, co-solvents can act to increase solubility of DTG in NMP while 
simultaneously limiting the amount of NMP required in ISFI formulations.  
 
Materials and Methods 
 
Materials 
50:50 Poly(DL-lactide-co-glycolide) (IV Range: 0.15 – 0.25 dL/g in HFIP, MW 10 kDa), 
50:50 Poly(DL-lactide-co-glycolide) (IV Range: 0.26 – 0.54 dL/g in HFIP, MW 27.2 kDa), 50:50 
Poly(DL-lactide-co-glycolide) (IV: 0.59 dL/g in HFIP, MW 53.4 kDa), 65:35 Poly(DL-lactide-co-
glycolide) (IV: 0.63 dL/g in HFIP, MW ~55 kDa), 75:25 Poly(DL-lactide-co-glycolide) (IV 
Range: 0.55 – 0.75 dL/g in CHCl3, MW ~55 kDa), 85:15 Poly(DL-lactide-co-glycolide) (IV: 0.66 
dL/g in CHCl3, MW ~55 kDa) were purchased from the LACTEL division of DURECT 
Corporation (Birmingham, AL USA). PharmasolveTM N-methyl-2-pyrrolidone (NMP) was 
purchased from Ashland (Wilmington, DE, USA). Dolutegravir was purchased from Advanced 
ChemBlocks Inc. (Burlingame, CA, USA). Lamivudine, Tween® 20, Tween® 80, Dimethyl 
Sulfoxide (DMSO) were all purchased from Thermo Fischer Scientific (Fair Lawn, NJ, USA). 
Labrasol, Gelucire (48/16 Pellets), and Gelucire (44/14) were generously provided by Gattefossé 
(Saint-Priest, France). Brij® 78 was purchased from CRODA Inc. (New Castle, DE, USA). D-
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alpha-tocopheryl polyethylene glycol-1000 succinate (Vitamin E TPGS) was purchased from 
Eastman Chemicals (Kingsport, TN, USA). Kolliphor® HS-15 (Solutol) and sodium azide were 
both purchased from Sigma-Aldrich (St. Louis, MO, USA). 
 
High-Performance Liquid Chromatography (HPLC) 
 A reverse-phase HPLC method was developed for each drug to effectively quantify the 
concentration of the drug released in vitro from the ISFI formulations. HPLC analysis was run on 
a Finnigan Surveyor HPLC System (includes RI Plus Detector, PDA Plus Detector, Autosampler 
Plus, and LC Pump Plus) with a Intersil ODS-3 column (5μm, 4.6mm x 150mm). Chromatographic 
separation for DTG was done by gradient elution using a mobile made of 0.1% trifluoroacetic acid 
(TFA) in deionized water and acetonitrile (ACN) (95:5 v/v, respectively) with a flow rate of 1.0 
mL/minute. The mobile phase used for 3TC was 50% deionized water with 50% ACN (1:1 v/v), 
at a flow rate of 0.7mL/min. 
 
Preparation of ISFI Formulations 
 In a 4 mL scintillation vial, a specific Poly(DL-lactide-co-glycolide) (PLGA) was added in 
a 1:2 (w/w) ratio with N-methyl-2-pyrrolidone (NMP).  In order to create a homogenous placebo 
formulation, mixture is sonicated (Branson 5510 Ultrasonic Cleaner) at 37°C until the PLGA is 
completely dissolved in NMP.  Drug was subsequently added to the PLGA/NMP solution and 
undergoes a process of intermittent heating and followed by a vortex to optimally dissolve the drug 
and produce an ISFI formulation with optimized drug concentration (10% w/w). To ensure 
complete drug dissolution and homogeneity in the formulation, sample aliquots (n=3) were 
collected from three different areas in the drug formulation, dissolved in acetonitrile, and the 
concentration of drug was quantified by HPLC analysis.   
 
Differential Scanning Calorimetry (DSC) 
 DSC was used to validate the physical state of the drug in the depot, i.e. crystalline or 
molecularly dispersed.  A change in the physical state of the drug can alter the release rate from 
the depot significantly. Factors that could influence the physical state of the drug: solubility of 
drug in the solvent, rate of diffusion with the solvent, solubility of drug in the polymer, and rate of 
PLGA precipitation. DSC analysis was done on pure drug, pure PLGA, ISFI placebo, and ISFI 
with drug (MK-2048 and DTG) using a differential scanning calorimeter (TA Q200, USA). 
Samples were weighed and sealed in an aluminum pan.  The DSC followed a heat/cool/heat 
method with starting temperature at 0°C ranging to 250°C, heating rate of 10°C/min, cooling rate 
of 5°C/min, under a helium atmosphere (flow rate 50 mL/min).  
 
In vitro Release Studies  
 In order to investigate the ability to fine-tune drug release kinetics with the ultra-long-
acting formulation, in vitro release studies were carried out with formulations containing DTG, 
FTC, or 3TC. To effectively evaluate drug release kinetics from the various ISFI formulations, 
approximately 13 mg (13 ± 3 mg) of formulation was injected into 200 mL of release media (0.01M 
phosphate buffered saline pH 7.4 with 2% solutol-HS and 0.02% sodium azide) and maintained at 
37°C. Aliquots (1 mL) are collected from the release medium at predetermined time points and 
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replaced with fresh release medium (1 mL). In order to avoid oversaturation and to maintain sink 
conditions, the release medium was replaced with fresh release medium (200 mL) every week. 
The aforementioned 1 mL samples were analyzed by HPLC to quantify the drug concentration 
released at each given time point. The concentration of drug was normalized by the total amount 
of drug in the injected implant.  
  
Determination of DTG Solubility in NMP with Cosolvents 
 The cosolvent and NMP solutions were created in varying ratios (1:9, 1:1, 9:1 
Cosolvent:NMP) and vortexed to create a homogenous solution.  ~10 mg of DTG was added into 
a 4mL vial, followed by ~100 mg of solvent.  The drug and solvent solution would sit for ~5 
minutes and then it would be gently heated and vortexed.  If the drug went into solution, more drug 
would be added in ~10 mg increments and vortexed as needed, until saturation was reached. The 
saturated solution is centrifuged in an Eppendorf Centrifuge 5415 R (20min, 13200rpm, 25°C).  
Three aliquots (n=3) were taken from the supernatant of the centrifuged vial and diluted 100x with 




Results and Discussion 
 
Effect of PLGA Molecular Weight on DTG Release Kinetics 
 
To investigate the effect of PLGA molecular weight (MW) on DTG release kinetics, ISFI 
formulations were prepared with constant drug concentration (DTG 80 mg/mL) and PLGA/NMP 
ratio (1:2) and varying PLGA MW (10, 27, and 54 kDa). Evident from Figure 1, the release rate 
increased for decreasing molecular weights. PLGA with higher MW (54 kDa) required greater 
time for hydrolysis of the ester linkages which resulted in a slower release of DTG (~28% at day 
30) compared to the ISFI formulation consisting of lower molecular weight PLGA (10 kDa), which 
exhibited the fastest release of DTG (~69% at day 30). The ISFI formulation made with the 
intermediate PLGA MW (27 kDa) exhibited an intermediate release profile (~51% at day 30).  The 
average release rates per week when zero order kinetics were achieved were 4.8% for the 10 kDa 




Figure 1.  Cumulative in vitro release of DTG from ISFIs with varying PLGA MW. Drug release 
studies were carried out under sink conditions in 0.01M PBS pH 7.4 at 37ºC. Drug concentration 
and PLGA/NMP weight ratio were maintained constant across all PLGA MWs. All error bars 
represent standard deviation with n = 3.  
 
 
Effect of GA:LA ratio in PLGA on DTG Release Kinetics 
 
PLGA are polymers consisting of ester linkages between glycolic acid and lactic acid. 
There is variability among the PLGAs in the ratio of glycolic acid to lactic acid present in the 
polymer.  In a subsequent study, we investigated the effect that the proportion of glycolic acid to 
lactic acid has on release kinetics of dolutegravir.  ISFI formulations containing a constant 
concentration of DTG (80 mg/mL), constant weight ratio of PLGA/NMP (1:2) and constant MW 
(~55 kDa) were prepared with PLGA having varying ratios of GA/LA (65:35, 75:25, and 85:15). 
It is evident that the formulation with the larger GA:LA ratio (85:15) released DTG at the highest 
rate, releasing at ~2.3% a week, the 75:25 GA:LA formulation released at 1.4% per week, and the 
65:35 GA:LA formulation released at 1.3% per week.  With respect to the percent release of DTG, 
at day 30 the ISFI formulation containing the highest amount of GA (PLGA 85:15 GA/LA) 
released ~47% of DTG compared to ~26% for the PLGA containing the lowest GA ratio (65:35 
























Figure 2.  Cumulative in vitro release of DTG from ISFIs containing PLGA with a range of 
GA/LA ratio. Drug release studies were carried out under sink conditions in 0.01M PBS pH 7.4 at 
37ºC. Drug concentration, PLGA/NMP weight ratio and PLGA MW were maintained constant 
across all ISFIs. All error bars represent standard deviation with n = 3.  
 
 
Effect of Drug Characteristics on their Release Kinetics from ISFI 
 
In addition to dolutegravir, lamivudine (Epivir®) a reverse transcriptase inhibitor and 
zalcitabine analog, and emtricitabine (Emtriva®), a nucleoside reverse transcriptase inhibitor, were 
tested to determine how the different drugs interact with the ISFI formulation and how this 
interaction influences their release kinetics in vitro. The formulations were created using 1:2 
PLGA/NMP (PLGA 50:50 GA/LA; MW 27 kDa) and adding 10% drug (w/w). This limits the 
variability only to the difference in characteristics of DTG, FTC, and 3TC. On average, the 
formulation depots containing 10% DTG (w/w) released ~91% of the drug in 18 weeks (average 
release rate = 5.04%/wk).  Comparatively, the formulation depots containing 10% 3TC (w/w) and 
10% FTC (w/w) had very similar release rates and released significantly faster than DTG. 
Approximately 91% of 3TC released in 12 days (average release rate ~ 7.6%/day) and ~93% of 

























Figure 3.  Cumulative in vitro release of DTG, FTC, and 3TC from ISFIs containing 1:2 w/w 
PLGA/NMP (PLGA 27 kDa) and 100 mg drug/mL. Drug release studies were carried out under 
sink conditions in 0.01M PBS pH 7.4 at 37ºC. Drug concentration, PLGA/NMP weight ratio and 
PLGA MW were maintained constant across all ISFIs. All error bars represent standard deviation 




Determination of DTG Solubility in NMP with Cosolvents 
  
 Our predicted HIV PrEP target human dose requirement of [DTG] is 300 mg/mL. In order 
to limit the amount of NMP (organic solvent class 2) [7] in ISFI formulations, cosolvents were 
tested to increase solubility of DTG in NMP. Different ratios were tested to determine what 
combination of NMP and cosolvent would be superior to NMP only. NMP alone has a saturation 
solubility of ~270 mg/mL for DTG (Table 1), and it remained the most effective stand-alone 
solvent, in terms of solubility. Each formulation was supersaturated and centrifuged to obtain a 
supernatant and drug pellet.  The supernatant was analyzed for drug concentration. Four solvents 
were shown to increase DTG solubility in a 9:1 ratio of NMP to cosolvent, respectively. DMSO, 
Tween® 20, Labrasol, and Gelucire (48/16) all increased DTG’s solubility to, on average, 304.9 





























Table 1: Maximum solubility of DTG in solvents. 
Solvent(s) Dolutegravir concentration (w/w) 
mg/mL (n=3) r SD 
NMP 269.84 r 7.02 
NMP:Gelucire (48/16) 90:10 349.62 r 19.21 
NMP:Gelucire (48/16) 50:50 114.09 r 0.24 
NMP:Brij® 78 90:10 227.68 r 1.32 
NMP:Vitamin E TPGS 90:10 239.19 r 5.45 
DMSO 60.23 r 9.71 
NMP:DMSO 90:10 304.95 r 0.87 
NMP/DMSO 50/50 247.29 r 12.00 
NMP:DMSO 10:90 136.90 r 18.49 
Tween® 20 12.62 r 1.40 
NMP:Tween® 20 90:10 303.45 r 7.33 
NMP:Tween® 20 50:50 81.81 r 5.86 
NMP:Tween® 20 10:90 15.09 r 0.80 
Tween® 80 7.42 r 2.59 
NMP:Tween® 80 90:10 253.67 r 32.22 
NMP:Tween® 80 50:50 102.28 r 22.33 
NMP:Tween® 80 10:90 18.85 r 2.97 
Labrasol 12.55 r 0.71 
NMP:Labrasol 90:10 324.23 r 16.35 
NMP:Labrasol 50:50 89.55 r 1.10 
NMP:Labrasol 10:90 17.83 r 4.12 
NMP:Gelucire (44/14) 90:10 272.76 r 4.59 
NMP:Gelucire (44/14) 50:50 90.70 r 7.27 
  
 
Differential Scanning Calorimetry  
 
The DSC analysis for pure drug (DTG and MK-2048), optimized placebo ISFI, and 
optimized drug loaded ISFIs (DTG and MK-2048 ISFIs) was carried out using a differential 
scanning calorimeter (TA Q200, USA). Samples varying in weight from 1-10 mg were weighed, 
hermetically sealed in an aluminum pan, and placed in the differential scanning calorimeter. The 
samples were subsequently heated from 25 – 250 °C, at a heating rate of 10°C/min, under nitrogen 
atmosphere (flow rate 20 mL/min). The thermograms were used to determine the peak glass 
transition temperature (Tg). 
Thermograms of neat PLGA and placebo ISFI (1:2 PLGA/NMP) show a broad 
endothermic peak at 41-44°C reflecting the amorphous nature of the PLGA 50:50. This peak also 
confirms the glass transition temperature of PLGA 50:50 which is in the range of 40-50°C. MK-
2048 and DTG ISFI formulations show endothermic peaks for MK-2048 and DTG at 194.51°C 
and 187.39°C respectively. This demonstrates that no chemical interaction took place between the 
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drug and polymer indicating that MK-2048 and DTG are both stable in the ISFI formulation.  
Figure 4-D also shows a PLGA endotherm at 42.37°C which shows that the glass transition 
temperature of PLGA is maintained in the presence of MK-2048 indicating the stability of PLGA 
in the presence of drug. 
 
Figure 4: Drug stability in ISFI formulation by DSC analysis. DSC thermograms: A) PLGA 
(neat), B) 1:2 PLGA/NMP Placebo ISFI, C) MK-2048 (neat), D) 0.8:1:2 MK-2048/PLGA/NMP 
ISFI, E) DTG (neat), F) 0.8:1:2 DTG/PLGA/NMP. DSC was used to characterize and ensure that 
the drug retains its chemical structure when in ISFI formulation.  The endotherms in D and F match 
those seen in C and E, respectively, showing that the drugs MK-2048 and DTG both retain physical 
structure in formulation. 
 
  
  Altering the molecular weight of the PLGA polymer in the in situ forming implant system 
had affected the release rates significantly.  The 53.4 kDa formulation depots released the slowest 
and the reaction rate increased as the molecular weight decreased.  Release of drug through the 
ISFI system initially occurs through diffusion, which is what is responsible for the initial burst 
released observed (Figure 1 and Figure 2) [4].  Lower molecular weight PLGAs undergo diffusion 
at a faster rate than larger PLGA formulations [5].  After initial diffusion of drug into the media 
system, continued release is achieved via degradation of the depot itself.  The polymer is made up 
of glycolic acid and lactic acid molecules bound together by ester linkages.  These ester linkages 
are broken through hydrolysis in the presence of water.  A higher molecular weight PLGA in 
formulation will thus degrade slower due to the increased number of ester linkages in the 
compound.  The 10 kDa PLGA formulation ISFI released DTG at an average rate of 4.78%/week 
 11 
(Figure 1) whereas the heaviest PLGA tested, 53.4 kDa, only released at an average rate of 
2.91%/week.  The 53.4 kDa formulation displayed the most viscosity largely due to the increased 
molecular weight of the PLGA polymer. 
 The structure of glycolic acid and lactic acid differ primarily in the presence of an 
additional methyl group side chain in lactic acid.  In Figure 5, the left group is lactic acid and the 
right group represents glycolic acid.  The methyl side 
chain reduces the hydrophilicity of lactic acid.  
Increasing the amount of lactic acid in a PLGA polymer 
will therefore further reduce the hydrophilicity of the 
system. This would result in a slower rate of degradation 
of ester linkages by hydrolysis in aqueous 
environments. The 65:35 GA/LA ISFI formulation 
released the slowest at an average rate of ~1.26%/week (Figure 2).  
This polymer was 35% lactic acid, as compared to the 85:15 ISFI formulation which released DTG 
at an average rate of ~2.33%/week (Figure 2) with the polymer only composed of 15% lactic acid.  
 Lamivudine is a reverse transcriptase inhibitor and zalcitabine analog used to treat HIV 
and HBV.  It is a relatively small compound with hydrophilic side chains.  Lipophilicity is a 
chemical property often used to describe the 
inherent hydrophilicity or hydrophobicity of a 
given drug.  LogP is the partition coefficient 
between lipophilic and aqueous phases that 
measures lipophilicity [3]. Lamivudine has a logP 
of -1.4 which indicates the majority of lamivudine is found in the aqueous phase, therefore it is a 
strongly hydrophilic drug.  Emtricitabine, a nucleoside reverse transcriptase inhibitor, has the same 
logP (-1.4), thus it shares similar hydrophilic qualities to lamivudine. Dissimilarly, dolutegravir’s 
logP is a positive value of 2.2, thus majority of its concentration is found in the lipophilic phase 
indicating a largely hydrophobic drug.  The hydrophilic nature of lamivudine means that the drug 
will have favorable interactions with aqueous solvent, NMP.  Therefore, when NMP diffuses from 
the formulation in release media both 3TC and FTC will favorably diffuse with NMP into media, 
accounting for the significant burst release seen in the first 24 hours (24 hour release 3TC = 47.3%, 
FTC = 51.6%) (Figure 3). Further, the hydrophilic nature of both drugs will facilitate hydrolysis 
of ester linkages in the ISFIs resulting in a faster release of 3TC and FTC. This pattern was 
observed with ~91% of lamivudine released within 12 days and 93% of FTC released in 2 weeks, 
as compared to ~91% of DTG released over 18 weeks (Figure 3).  
 N-methyl-2-pyrrolidone is a Class 2 solvent as per the FDA’s list of biocompatible solvents  
[7].  This suggests that NMP should be limited in use in pharmaceuticals due to its inherent 
toxicity. Less toxic cosolvents, in addition to increasing drug solubility in NMP, can also reduce 
the amount of NMP necessary in an ISFI.  Four cosolvents showed a significant increase in the 
solubility of DTG in NMP: Tween 20, Gelucire (48/16), Labrasol, and DMSO. Adding these 
cosolvents in a 1:9 ratio, cosolvent to NMP, reduces the amount of NMP used in the formulation 
Figure 5: PLGA  
Equation 1 [3]:  
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and simultaneously increases the amount of DTG that can be homogenously added to the ISFI 
formulation. The predicated HIV PrEP human dose requirement of [DTG] ≥ 300 mg/mL can more 





When working on long-acting drug delivery systems, it is important to understand the 
variability that is possible.  Specifically, the makeup of in situ forming implants allows for the 
associated release kinetics of drugs to be manipulated through variation of the individual 
components. The degradation of depots increases with a smaller molecular weight of a PLGA. 
This results in a faster release of DTG as compared to formulations containing higher molecular 
weights. Similarly, a larger proportion of glycolic acid in a PLGA will result in faster degradation 
due to hydrolysis of ester linkages caused by its more hydrophilic tendencies. More hydrophilic 
drugs release faster due to their favorable interactions in aqueous environments as seen with 
lamivudine and emtricitabine (logP = -1.4). Affecting release kinetics through compositional 
changes can serve as a critical advantage when developing treatments for populations. Cosolvents 
can increase DTG solubility in NMP via favorable chemical interactions with DTG to bring it into 
solution. Increasing the solubility of DTG in the formulation and decreasing the amount of NMP 
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